Pegylated liposomal doxorubicin (Duomeisu®) monotherapy in patients with HER2-negative metastatic breast cancer heavily pretreated with anthracycline and taxanes: a single-arm, phase II study

被引：0
|
作者：
Hanfang Jiang
Huiping Li
Guohong Song
Lijun Di
Bin Shao
Ying Yan
Xiaoran Liu
Yifei Chen
Ruyan Zhang
Ran Ran
Yaxin Liu
Xinyu Gui
Nan Wang
Huan Wang
机构：
[1] Peking University Cancer Hospital & Institute,Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Breast Oncology
来源：
Breast Cancer Research and Treatment | 2023年 / 199卷
关键词：
Pegylated liposomal doxorubicin; Metastatic breast cancer; HER2-negative; Efficacy; Safety;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：67 / 79
页数：12
相关论文
共 50 条
  • [31] Multicenter Phase II Study of Pegylated Liposomal Doxorubicin in Combination with Vinorelbine as First-Line Treatment in Elderly Patients with Metastatic Breast Cancer
    Mlineritsch, Brigitte
    Schabel-Moser, Renate
    Andel, Johannes
    Fridrik, Michael
    Moik, Martin
    Mayer, Peter
    Russ, Gudrun
    Rass, Christof
    Greil, Richard
    ONKOLOGIE, 2009, 32 (1-2): : 18 - 24
  • [32] Pegylated liposomal doxorubicin and gemcitabine in the front-line treatment of recurrent/metastatic breast cancer: a multicentre phase II study
    V Adamo
    V Lorusso
    R Rossello
    B Adamo
    G Ferraro
    D Lorusso
    G Condemi
    D Priolo
    L Di Lullo
    A Paglia
    S Pisconti
    G Scambia
    G Ferrandina
    British Journal of Cancer, 2008, 98 : 1916 - 1921
  • [33] Pegylated liposomal doxorubicin and gemcitabine in the front-line treatment of recurrent/metastatic breast cancer: a multicentre phase II study
    Adamo, V.
    Lorusso, V.
    Rossello, R.
    Adamo, B.
    Ferraro, G.
    Lorusso, D.
    Condemi, G.
    Priolo, D.
    Di Lullo, L.
    Paglia, A.
    Pisconti, S.
    Scambia, G.
    Ferrandina, G.
    BRITISH JOURNAL OF CANCER, 2008, 98 (12) : 1916 - 1921
  • [34] Metronomic oral combination chemotherapy with capecitabine and cyclophosphamide: a phase II study in patients with HER2-negative metastatic breast cancer
    Masataka Yoshimoto
    Shintaro Takao
    Masaru Hirata
    Yasushi Okamoto
    Sumio Yamashita
    Yoshihiro Kawaguchi
    Makoto Takami
    Hidemi Furusawa
    Satoshi Morita
    Chigusa Abe
    Junichi Sakamoto
    Cancer Chemotherapy and Pharmacology, 2012, 70 : 331 - 338
  • [35] Penpulimab, an anti-PD-1 antibody, for heavily pretreated metastatic nasopharyngeal carcinoma: a single-arm phase II study
    Chen, Xiaozhong
    Wang, Wei
    Zou, Qingfeng
    Zhu, Xiaodong
    Lin, Qin
    Jiang, Yi
    Sun, Yan
    Shen, Liangfang
    Wang, Lin
    Zou, Guorong
    Lin, Xiaoyan
    Lin, Shaojun
    Li, Minying
    Wang, Ying
    Xu, Ruilian
    Ao, Rui
    Wang, Rensheng
    Lin, Haifeng
    Huang, Shuang
    Xu, Tingting
    Li, Wenting
    Xia, Mengying
    Xia, Yu
    Wang, Zhongmin
    Li, Baiyong
    Li, Jingao
    Hu, Chaosu
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2024, 9 (01)
  • [36] First line therapy with paclitaxel (Taxol®) and pegylated liposomal doxorubicin (Caelyx®) in patients with metastatic breast cancer:: a multicentre phase II study
    Vorobiof, DA
    Rapoport, BL
    Chasen, MR
    Slabber, C
    McMichael, G
    Eek, R
    Mohammed, C
    BREAST, 2004, 13 (03) : 219 - 226
  • [37] Phase I-II study of pegylated liposomal doxorubicin combined with weekly paclitaxel as first-line treatment in patients with metastatic breast cancer
    Bourgeois, Hugues
    Ferru, Aurelie
    Lortholary, Alain
    Delozier, Thierry
    Boisdron-Celle, Michelle
    Abadie-Lacourtoisie, Sophie
    Joly, Florence
    Chieze, Stephanie
    Chabrun, Virginie
    Gamelin, Erick
    Tourani, Jean-Marc
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2006, 29 (03): : 267 - 275
  • [38] Phase II study of weekly paclitaxel and trastuzumab in anthracycline- and taxane-pretreated patients with HER2-overexpressing metastatic breast cancer
    S Gori
    M Colozza
    A M Mosconi
    E Franceschi
    C Basurto
    R Cherubini
    A Sidoni
    A Rulli
    C Bisacci
    V De Angelis
    L Crinò
    M Tonato
    British Journal of Cancer, 2004, 90 : 36 - 40
  • [39] Phase II study of weekly paclitaxel and trastuzumab in anthracycline- and taxane-pretreated patients with HER2-overexpressing metastatic breast cancer
    Gori, S
    Colozza, M
    Mosconi, AM
    Franceschi, E
    Basurto, C
    Cherubini, R
    Sidoni, A
    Rulli, A
    Bisacci, C
    De Angelis, V
    Crinò, L
    Tonato, M
    BRITISH JOURNAL OF CANCER, 2004, 90 (01) : 36 - 40
  • [40] Safety of eribulin as third-line chemotherapy in HER2-negative, advanced breast cancer pre-treated with taxanes and anthracycline: OnSITE study
    Manso, Luis
    Moreno Anton, Fernando
    Izarzugaza Peron, Yann
    Delgado Mingorance, Juan, I
    Borrega Garcia, Pablo
    Echarri Gonzalez, Maria J.
    Martinez-Janez, Noelia
    Lopez-Gonzalez, Ana
    Olier Garate, Clara
    Ballesteros Garcia, Anabel
    Chacon Lopez-Muniz, Ignacio
    Ciruelos Gil, Eva
    Angel Garcia-Saenz, Jose
    Paz-Ares, Luis
    BREAST JOURNAL, 2019, 25 (02) : 219 - 225
12345